AVEO Oncology announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology?s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development. Dr. Braendle brings more than twenty years of clinical research experience to AVEO Oncology, most recently serving as Chief Development Officer of Autolus Therapeutics Plc since July 2021, where he was responsible for all development functions and the conduct of the pivotal program of AUCATZYL? (a CD-19 directed genetically modified autologous T cell immunotherapy) in adult acute lymphoblastic leukemia, and the respective filing to the U.S. Food & Drug Administration and European Medicines Agency.

Prior to his time at Autolus, Dr. Braendle held the role of Executive Vice President, Chief Medical Officer and Global Head of Development at Sumitomo Dainippon Pharma Oncology, where he was responsible for a full range of development functions and progressed several early-stage, first in human programs and late-stage programs. Prior to this, Dr. Braendle served as President and CEO of ARUP Laboratories, a national clinical and anatomic reference laboratory. Dr. Braendle also spent over a decade at Novartis AG, where he served as Senior Vice President and Global Head of Companion Diagnostics and led the company's precision medicine approach. Dr. Braendle received his medical degree at RWTH Aachen University in Germany, followed by specialty training in medical oncology, urology and pharmacology.

Dr. Braendle is also an associate professor at the University of Ulm, Germany. The company announced the formation of its Scientific Advisory Committee. This esteemed group of experts in oncology research and clinical development were selected to advise and bring unique perspectives to AVEO and LG Chem?s clinical strategy and business development initiatives.

The Scientific Advisory Committee is comprised of several leading cancer experts, including: Al B. Benson III, MD, FACP, FACCC, FASCO; Professor of Medicine; Associate Director from Cooperative Groups; Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Scott Kopetz, MD, PhD; Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology; Division of Cancer Medicine; University of Texas MD Anderson Cancer Center. D. Ross Camidge, MD, PhD; Professor of Medicine/Oncology; Joyce Zeff Chair in Lung Cancer; Director, Thoracic Oncology; Faculty, Developmental Therapeutics Program; University of Colorado Cancer Center, Aurora.

John L. Marshall, MD; Chief, Hematology and Oncology; Professor of Medicine and Oncology; Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers Georgetown Lombardi Comprehensive Cancer Center. Edward Chu, MD, MMS; Director, Montefiore Einstein Cancer Center; Albert Einstein College of Medicine. Tony S.K. Mok, BBS, FASCO; Chairman, Department of Clinical Oncology; LiShu Fan Professor of Clinical Oncology; The Chinese University of Hong Kong.

Ezra Cohen, MD, FRCPSC, FASCO; Chief Medical Officer of Oncology; Tempus; University of California- San Diego. Paul G. Richardson, MD; Director, Clinical Research; Jerome Lipper Multiple Myeloma Center; Dana-Farber Cancer Institute. Kevin J. Cullen, MD; Professor of Oncology; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center; University of Maryland School of Medicine.

Joseph Tabernero, MD, PhD; Head, Medical Oncology Department; Director, Vall d?Hebron Institute of Oncology; Professor of Medicine, UVic-UCC. Enrique Grande, MD, PhD, Msc; Director, Medical Oncology Program and Clinical Research lead; MD Anderson Cancer Center Madrid. Jan Vermorken, MD, PhD; Emeritus Professor of Oncology; Department of Medical Oncology; Antwerp University Hospital.